|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-10-25
|
|
pubmed:abstractText |
The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
pubmed-author:AbbolitoM RMR,
pubmed-author:AloyGG,
pubmed-author:BottiCC,
pubmed-author:BuonomoOO,
pubmed-author:CarlinoMM,
pubmed-author:CaroneM DMD,
pubmed-author:ChiappettaN RNR,
pubmed-author:CognettiFF,
pubmed-author:ContiFF,
pubmed-author:D'AlessandroRR,
pubmed-author:FerroniPP,
pubmed-author:GuadagnoLL,
pubmed-author:MariottiSS,
pubmed-author:PerriPP,
pubmed-author:RicciottiAA,
pubmed-author:RoselliMM,
pubmed-author:SpilaAA,
pubmed-author:VickRR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9-19
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:11678313-Adolescent,
pubmed-meshheading:11678313-Adult,
pubmed-meshheading:11678313-Aged,
pubmed-meshheading:11678313-Aged, 80 and over,
pubmed-meshheading:11678313-Breast Neoplasms,
pubmed-meshheading:11678313-Carcinoma, Ductal, Breast,
pubmed-meshheading:11678313-Carcinoma, Lobular,
pubmed-meshheading:11678313-Case-Control Studies,
pubmed-meshheading:11678313-Disease-Free Survival,
pubmed-meshheading:11678313-Female,
pubmed-meshheading:11678313-Fibrocystic Breast Disease,
pubmed-meshheading:11678313-Humans,
pubmed-meshheading:11678313-Italy,
pubmed-meshheading:11678313-Longitudinal Studies,
pubmed-meshheading:11678313-Mastectomy,
pubmed-meshheading:11678313-Middle Aged,
pubmed-meshheading:11678313-Mucin-1,
pubmed-meshheading:11678313-Neoadjuvant Therapy,
pubmed-meshheading:11678313-Neoplasm Metastasis,
pubmed-meshheading:11678313-Neoplasm Recurrence, Local,
pubmed-meshheading:11678313-Neoplasm Staging,
pubmed-meshheading:11678313-Peptides,
pubmed-meshheading:11678313-Postoperative Period,
pubmed-meshheading:11678313-Sensitivity and Specificity,
pubmed-meshheading:11678313-Tumor Markers, Biological
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
|
|
pubmed:affiliation |
Laboratory of Clinical Pathology, Regina Elena Cancer Institute, University of Rome Tor Vergata, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
